Forest Laboratories Inc., the drugmaker being acquired by Actavis Plc, agreed to buy Furiex Pharmaceuticals Inc. for $1.1 billion in cash to expand offerings of medicines for digestive disorders.

Forest, based in New York, will pay about $95 a share for Furiex, and up to $30 a share in a contingent value right for Furiex’s eluxadoline, a treatment for irritable bowel syndrome, based on the drug’s approval, Forest said today in a statement.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.